Nasrin Asgari

TL;DR: The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal.

TL;DR: In this article, the authors proposed indications for MOG-IgG testing based on expert consensus, and gave a list of conditions atypical for MG-EM (red flags) that should prompt physicians to challenge a positive MOG IgG test result, and provided recommendations regarding assay methodology, specimen sampling and data interpretation.

TL;DR: MRI findings of neuromyelitis optica and its spectrum disorder (NMOSD) are reviewed, finding brain, optic nerve, and spinal cord MRI findings of NMOSD to be of increased interest.

TL;DR: Indications for MOG-IgG testing based on expert consensus are proposed and a list of conditions atypical for Mog-EM (“red flags”) are given that should prompt physicians to challenge a positive Mogenogenetically distinct test result.

TL;DR: This is the largest cohort studied for IgG to human full-length MOG by means of an up-to-date CBA and finds MOG-IgG is present in a substantial subset of patients with ON and/or myelitis, but not in classical MS.